Medical Device Global Market Access

This episode delves into the growing use of agentic AI for drafting complex regulatory dossiers like FDA 510(k)s and EU Technical Files. We explore the paradox where AI's speed in drafting is offset by a massive bottleneck: the intensive, time-consuming process of human-in-the-loop validation. Discover why this crucial verification step is non-negotiable and how it's reshaping the role of regulatory professionals, preventing the promised acceleration to market. Key Questions: - What is "agentic AI" and how is it changing MedTech regulatory submissions? - Why is the dream of fully automated dossier creation still out of reach? - What is the "human-in-the-loop" validation bottleneck and why is it critical? - How can you leverage AI's power for submissions without compromising on compliance? - What are the legal and practical risks of over-relying on AI for regulatory files? - Is your regulatory team prepared for the new skills needed to manage AI tools? - How does a balanced "co-pilot" approach to AI optimize your submission strategy? Pure Global helps MedTech and IVD companies navigate these modern regulatory challenges. We combine deep local expertise with advanced AI tools to streamline your global market access. Our services assist in developing efficient regulatory strategies and compiling technical dossiers, ensuring accuracy while leveraging technology to accelerate processes. Instead of getting bogged down by validation, let our experts and AI-powered platforms manage your submissions efficiently across more than 30 markets. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to learn more.

This episode explores the growing threat of 'digital darkness'—total network outages caused by cyberattacks—and its impact on the medical device industry. We delve into the heightened scrutiny from regulatory bodies like the FDA and under the EU MDR, focusing on new requirements for manufacturers to prove their devices can function safely and effectively offline. We discuss key strategies for building cybersecurity resilience, from design and risk assessment to post-market surveillance. Key Questions - What is "digital darkness" and why is it a top concern for hospitals? - How are the FDA and EU regulators changing their cybersecurity requirements for medical devices? - What must manufacturers now demonstrate about their device's offline capabilities? - Why has a Software Bill of Materials (SBOM) become a critical submission document? - What are effective strategies for designing devices that are resilient to network failure? - How does post-market surveillance play a role in managing cybersecurity risks? - What are the consequences for manufacturers who fail to meet these new standards? Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, ensuring your products meet complex global standards, including cybersecurity. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, helping you navigate demanding requirements from bodies like the FDA and EU. We act as your local representative in over 30 markets, managing the entire lifecycle from initial submission to post-market surveillance. Let us help you achieve faster global market access. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the pivotal shift from traditional clinical trial data to the increasing demand for continuous Real-World Evidence (RWE) for medical devices. We delve into why global regulators and payers now require robust post-market data to prove a device's long-term safety, effectiveness, and value. We also unpack the significant infrastructure and analytical challenges that MedTech companies face in building a compliant and effective RWE program. Key Questions: - What is the difference between Real-World Data (RWD) and Real-World Evidence (RWE)? - Why are traditional clinical trials no longer sufficient for market approval and reimbursement? - How do new regulations like the EU MDR impact post-market data collection requirements? - What specific evidence are payers looking for to determine a device's cost-effectiveness? - What are the main challenges companies face when building an RWE generation system? - How can a strong RWE strategy provide a competitive advantage? As regulatory demands for Real-World Evidence intensify, having a proactive strategy is essential. Pure Global helps MedTech and IVD companies design and implement robust post-market surveillance and data analysis programs. Our blend of local regulatory expertise and advanced AI tools simplifies the process of gathering, analyzing, and submitting the evidence needed to maintain and expand global market access. We turn your post-market obligations into a strategic advantage. To learn more about our services, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the EU's new Artificial Intelligence Act and its significant impact on medical device manufacturers. We explore the "high-risk" classification for most AI-driven medical devices, the new compliance obligations that run parallel to existing MDR/IVDR requirements, and the critical timelines manufacturers must meet. We break down the challenges and strategies for navigating this dual regulatory framework, from data governance to human oversight. - What is the EU AI Act and why is it critical for MedTech companies? - How are AI-powered medical devices classified under this new regulation? - What are the new, specific compliance requirements beyond MDR and IVDR? - How does the conformity assessment process work for both the AI Act and MDR/IVDR? - Are you required to get two separate certifications? - What is the key compliance deadline that all manufacturers must have on their calendar? - How should you prepare your Quality Management System and technical documentation for this dual framework? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. We act as your local representative in over 30 markets, developing efficient regulatory strategies to get your products approved faster. Our AI-powered platforms help compile and manage technical dossiers for seamless submissions to authorities in the EU and beyond. Whether you're a startup or a multinational, we provide tailored solutions for market access and continuous compliance. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode breaks down the FDA's final rule transitioning the Quality System Regulation (21 CFR Part 820) to the ISO 13485-aligned Quality Management System Regulation (QMSR). We cover the February 2, 2026, compliance deadline, the key differences and retained FDA requirements, and the strategic steps medical device manufacturers must take to harmonize their global quality documentation and ensure a seamless transition. - What is the FDA's new Quality Management System Regulation (QMSR)? - When is the mandatory deadline to transition from QSR to QMSR? - How does the new rule align with the global standard ISO 13485? - Why is simply having an ISO 13485 certificate not enough for compliance? - Which specific U.S. requirements are being kept in the new QMSR? - What are the biggest challenges in harmonizing global quality documents? - What is the first step your company should take to prepare for the 2026 deadline? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. Navigating the FDA's transition to the QMSR while managing global registrations requires expert strategy. We develop efficient pathways for regulatory approval, using advanced AI to compile and manage technical dossiers that meet both new QMSR and international standards. Our local experts in over 30 markets ensure your quality systems are compliant globally. Let us streamline your transition and accelerate your global market access. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the critical capacity crisis among Notified Bodies under the EU's Medical Device Regulation (MDR). We explore how the stringent requirements of the MDR, combined with a reduction in the number of designated Notified Bodies, have created a massive bottleneck for certifying new and legacy medical devices. We discuss the significant risk this poses to manufacturers, who face the possibility of their products being forced off the market as old certificates expire, and examine the European Commission's legislative response to extend the transition deadlines. - What is the EU MDR Notified Body capacity crisis? - Why are there multi-year delays for device certification in Europe? - How did the transition from the MDD to the MDR create a market bottleneck? - What are the crucial deadlines of May and September 2024 for legacy devices? - Could your medical device be forced off the EU market due to expiring certificates? - What steps did the European Commission take to prevent a widespread device shortage? - How does the risk class of your device affect its new transition deadline? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access with local expertise and advanced AI, helping you navigate complex challenges like the EU MDR. Our services include developing efficient regulatory strategies, compiling technical dossiers with AI, and acting as your local representative in over 30 markets. We help you meet critical deadlines and maintain market presence. For support with your global expansion, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode dives into one of the most significant challenges facing medical device manufacturers in 2026—the mandatory EUDAMED registration deadline. We break down what the May 2026 milestone means, the complexities of uploading technical and Unique Device Identification (UDI) data, and the critical steps companies must take now to avoid being locked out of the European Union market. Key Questions: - What is the EUDAMED and why is it critical for EU market access? - When is the final deadline for mandatory EUDAMED registration? - What specific data, including UDI information, must be uploaded? - What are the consequences of failing to meet the 2026 EUDAMED requirements? - How does the new database impact post-market surveillance and transparency? - What are the biggest data management challenges manufacturers face with this new system? - How can you prepare your technical dossiers for a seamless EUDAMED submission? Struggling to prepare for complex regulatory shifts like the EUDAMED deadline? Pure Global offers end-to-end consulting for MedTech and IVD companies, streamlining global market access. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, ensuring compliance with evolving standards. We act as your local representative in over 30 markets, including the EU, managing the entire registration process. To secure your market presence and navigate deadlines with confidence, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed breakdown of the medical device registration fees charged by Singapore's Health Sciences Authority (HSA). We cover the standard application fee and the specific evaluation costs for Class B, Class C, and Class D devices. The host explains how different evaluation routes—such as Full, Abridged, Expedited, and Immediate—impact the final cost and how leveraging prior approvals from reference agencies can lead to significant savings. - What are the latest HSA registration fees for medical devices in Singapore as of August 2024? - How do evaluation costs differ between Class B, Class C, and Class D devices? - What is the difference in cost between a Full, Abridged, and Expedited evaluation route? - Can prior approval from the US FDA or a European Notified Body reduce my Singapore registration fees? - What is the standard application fee for all device classes? - How can a strategic approach to registration save thousands of dollars per application? - What costs are not included in the official HSA fees? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies looking to enter markets like Singapore. Our team of local experts, combined with advanced AI and data tools, can help you develop the most efficient regulatory strategy, prepare your technical dossier, and act as your local representative. We streamline the global market access process, helping you navigate complex fee structures and regulatory requirements to get your product to market faster. For more information, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Singapore's mandatory Good Distribution Practice for Medical Devices (GDPMDS) certification. We explore the governing standard, SS 620:2016, and explain why it is an essential requirement enforced by the Health Sciences Authority (HSA) for any company seeking to import or wholesale medical devices in this key Asian market. Learn about the core components of the standard, from quality management systems to traceability and storage, to ensure your supply chain is compliant. - What is GDPMDS and why is it mandatory for market access in Singapore? - How does the SS 620:2016 standard impact medical device importers and wholesalers? - What are the key pillars of a compliant Quality Management System under GDPMDS? - Why is traceability a critical component of Singapore's distribution requirements? - What role does the Health Sciences Authority (HSA) play in enforcing these regulations? - Are there specific requirements for storage, stock rotation, and handling recalls? Pure Global offers end-to-end regulatory consulting to streamline global market access for MedTech and IVD companies. We act as your local representative in over 30 markets, including Singapore, developing efficient regulatory strategies and using advanced AI to compile technical dossiers. This ensures you meet critical requirements like GDPMDS for faster approvals. Our experts manage the entire process, from initial submission to post-market surveillance, ensuring your continued compliance. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your market entry.

This episode provides a detailed guide to the three types of medical device dealer licenses required by Singapore's Health Sciences Authority (HSA): manufacturer, importer, and wholesaler. We clarify the specific activities each license permits and highlight the critical, non-negotiable requirement for a compliant Quality Management System (QMS), referencing key standards like GDPMDS and ISO 13485. - What are the three types of dealer licenses for medical devices in Singapore? - If I import a device, do I automatically have the right to sell it wholesale? - What is the difference between an importer's and a wholesaler's license under HSA? - What Quality Management System (QMS) certifications does the HSA accept? - Is an ISO 13485 certificate always sufficient for a Singapore dealer license application? - What is GDPMDS and why is it important for Singapore market access? - Do manufacturers in Singapore need a separate license to sell their own products? - Are there any license exemptions for low-risk medical devices? Navigating complex regulations like Singapore's dealer licensing is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, acting as your local representative and using advanced AI to streamline dossier submission. Our experts ensure your Quality Management System meets HSA standards, paving a smoother path to market entry. Whether you're a startup or a multinational, we can help you access over 30 global markets faster. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into a key regulatory pathway in Singapore for low-risk medical devices. We explore the Health Sciences Authority's (HSA) exemption from product registration for Class A non-sterile devices, a crucial topic clarified by guidance from June 1, 2022. We detail the specific requirements that are waived, as well as the crucial obligations that remain, such as dealer licensing and post-market surveillance. This is essential listening for any MedTech company looking to enter the Singaporean market efficiently with a low-risk product portfolio. - What is Singapore's Class A medical device registration exemption? - Does my low-risk, non-sterile device need to be registered with the HSA? - If product registration is not required, what licenses do I still need? - What are the post-market responsibilities for exempt devices in Singapore? - Who is responsible for correctly classifying a medical device to qualify for the exemption? - How can this pathway accelerate my entry into the Singaporean market? Pure Global streamlines global market access for MedTech and IVD companies. For Singapore, we act as your local representative, manage dealer licensing, and ensure your regulatory strategy leverages pathways like the Class A exemption. Our experts, supported by advanced AI tools, help you compile technical dossiers and manage post-market compliance, ensuring a fast and compliant entry. Access over 30 markets with our end-to-end solutions. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed guide on using the ASEAN Common Submission Dossier Template (CSDT) for medical device registration in Singapore. We cover the structure of the CSDT, specific documentation required by Singapore's Health Sciences Authority (HSA), and how requirements vary based on device risk classification, ensuring you have the information to prepare a successful submission. - What is the ASEAN Common Submission Dossier Template (CSDT)? - How does the CSDT streamline medical device registration in Southeast Asia? - What are the essential components of a CSDT technical file for Singapore's HSA? - How do documentation requirements differ for Class A, B, C, and D devices in Singapore? - What are the common pitfalls to avoid when preparing your submission? - Why is a robust risk management file compliant with ISO 14971 crucial for HSA approval? - What specific labeling requirements must be met for the Singaporean market? Need to navigate the complexities of global markets like Singapore? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We leverage local expertise in over 30 markets and advanced AI tools to streamline your market access strategy, technical dossier preparation, and registration submissions. Our services ensure your product meets all local requirements, from initial strategy to post-market surveillance. Let us be your local representative and partner in global expansion. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Singapore's Health Sciences Authority (HSA) abridged evaluation route, a streamlined pathway for medical device registration. We detail how manufacturers can leverage prior approvals from five major reference agencies—including the US FDA and EU Notified Bodies—to accelerate market access for Class B, C, and D devices in this key ASEAN hub. - What are Singapore's five reference regulatory agencies for medical devices? - How can a US FDA approval or EU CE Mark speed up your registration in Singapore? - What is the HSA's abridged evaluation route and how does it work? - Which medical device classes are eligible for this streamlined process? - What specific documentation is required to utilize the abridged pathway? - Does using a reference approval guarantee registration with the HSA? - Why is Singapore considered a strategic first market for expanding into the ASEAN region? Pure Global offers end-to-end consulting for MedTech and IVD companies, streamlining global market access with a powerful combination of local expertise and advanced AI tools. We develop efficient regulatory strategies and act as your local representative to get your products approved and ready for sale in over 30 markets, including Singapore. Our experts use AI to efficiently compile, manage, and submit the technical dossiers required for pathways like the abridged route. To learn how we can accelerate your global expansion, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the mandatory requirement for foreign medical device manufacturers to appoint a Singapore Registrant. We explain the role and responsibilities of this local authorized representative as required by the Health Sciences Authority (HSA), the strategic implications of choosing a representative, and how it impacts market access for Class B, C, and D devices. - What is a Singapore Registrant and why is it mandatory for foreign manufacturers? - Who is eligible to act as a local authorized representative in Singapore? - What are the key legal responsibilities of the company holding the device license? - How does the Registrant control your medical device registration and market access? - Should your distributor also be your Singapore Registrant? - What happens to your HSA registration if you decide to change distributors? - Which medical device risk classes require the appointment of a local Registrant? Pure Global offers expert, independent local representation to act as your Singapore Registrant, ensuring you maintain full control over your device licenses. Our services streamline the HSA registration process, from compiling technical dossiers using advanced AI to managing post-market surveillance. By separating regulatory ownership from distribution, we provide MedTech and IVD companies with the flexibility to scale their business in Singapore and beyond. To secure your market access and build a resilient regulatory strategy, contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools at https://pureglobal.ai/.

This episode provides a detailed guide to the Singapore Health Sciences Authority (HSA) medical device registration pathways for Class B, C, and D devices. We explore the four main evaluation routes—Full, Abridged, Expedited, and Immediate—and explain how leveraging prior approvals from key international reference agencies like the US FDA and EU Notified Bodies can significantly accelerate your product's entry into the Singaporean market. - What are Singapore's four main evaluation routes for medical devices? - How can a US FDA approval or CE Mark speed up your HSA registration? - Which pathway is required for a novel device with no other market approvals? - What are the specific criteria for the Abridged route for Class B, C, and D devices? - Can your high-risk Class C or D device qualify for an Expedited review? - What are the requirements to get a Class B device registered almost immediately? - Which five global regulatory bodies does Singapore's HSA recognize? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We act as your local representative in over 30 markets, developing efficient regulatory strategies to get your product approved faster. Our advanced AI and data tools streamline the compilation and submission of technical dossiers, helping you identify the best markets for expansion. Whether you are a startup or a multinational, our integrated approach allows a single registration process to access multiple markets, combining global reach with local expertise. Contact us at [email protected] or visit https://pureglobal.com. Explore our FREE AI tools at https://pureglobal.ai.

This episode provides a detailed guide to Singapore's Health Sciences Authority (HSA) medical device risk classification system. We explore the four-tier structure (Class A to Class D), explain how it aligns with international GHTF/IMDRF principles, and discuss how factors like intended use and invasiveness determine a device's class. Understanding this foundational step is crucial as it dictates the entire regulatory pathway for market access in Singapore. Key Questions: - What are the four risk classes for medical devices in Singapore? - How does the HSA classify a device based on its intended use and technology? - Why is Singapore's system aligned with global standards like the GHTF? - What are some examples of Class A, B, C, and D devices? - How does risk classification impact the registration process and timeline? - What are the consequences of incorrectly classifying your medical device? - Which devices might be exempt from pre-market registration in Singapore? Navigating Singapore's regulatory landscape requires local expertise and strategic planning. Pure Global specializes in helping MedTech and IVD companies achieve market access in over 30 countries, including key Asia Pacific markets like Singapore. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative. By leveraging advanced AI and data tools, we streamline the process, ensuring your device is classified correctly and your submission is optimized for success. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your global expansion.

This episode provides a detailed overview of Singapore's medical device registration framework. We cover the role of the Health Sciences Authority (HSA), the foundational Health Products Act 2007 and Medical Devices Regulations 2010, the four-tiered risk classification system, and the various registration pathways available to manufacturers based on prior approvals in reference markets. - What is the primary legislation governing medical devices in Singapore? - How does the Health Sciences Authority (HSA) classify medical devices by risk? - What are the different registration pathways available for market entry? - Which countries are considered reference markets by the HSA? - Can approval from another country speed up your Singapore registration? - What is the ASEAN CSDT and why is it important for your submission? - Is a local representative required to register a medical device in Singapore? - Are all device classes required to undergo full product registration? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We leverage local expertise and advanced AI tools to streamline global market access, acting as your local representative in over 30 markets, including Singapore. Our services cover the entire product lifecycle, from regulatory strategy and technical dossier submission to post-market surveillance. Let us help you navigate complex frameworks efficiently. For more information, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of the regulatory requirements for medical device labeling, Instructions for Use (IFU), and Spanish translation for market entry into Colombia. We explore the specific rules set by the national authority, INVIMA, and explain how these elements are meticulously evaluated during the registration process to ensure patient safety and device efficacy. - What is INVIMA's primary language requirement for medical device labels in Colombia? - Which Colombian decree governs the rules for labeling and IFUs? - How does an inaccurate Spanish translation affect the device registration timeline? - What specific information must be included on a label for the Colombian market? - Why is a professional, technical translation of the IFU so critical for approval? - What are the most common pitfalls manufacturers face with labeling submissions to INVIMA? - How does INVIMA verify the accuracy of translated materials? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We specialize in navigating complex requirements like those in Colombia, acting as your local representative in over 30 markets. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, minimizing rejections. From initial market research to post-market surveillance, Pure Global ensures your products meet all local standards for a faster path to market. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode provides a detailed breakdown of the costs associated with registering a medical device in Colombia with the regulatory authority, INVIMA. We cover the official government application fees based on risk classification, as well as essential ongoing costs such as renewals, modification fees, and the expenses related to local representation and translation services, giving you a complete financial picture for market entry. - What are the official INVIMA government fees for medical device registration in Colombia? - How does the risk class of a device affect the registration cost? - Are there costs other than the government application fees? - What are the ongoing maintenance costs for a medical device registration in Colombia? - How much are renewal fees and how often are they required? - Do I need to budget for translation services? - Is a local legal representative required and what are the associated costs? - What happens if I need to make a modification to my registered device? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Colombia, developing efficient regulatory strategies and using advanced AI to compile and submit technical dossiers. Our services ensure ongoing compliance through post-market surveillance and continuous regulatory monitoring. By integrating local expertise with data-driven tools, we help you navigate complex environments and expand your global footprint. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the requirements for medical device registration in Colombia, focusing on whether prior approval from a reference country like the US or EU is mandatory. We detail the role of a Certificate of Free Sale (CFS), the different regulatory pathways defined by INVIMA based on device risk classification (Class I, IIa, IIb, III), and the specific process available for novel devices that have not yet received marketing authorization in any country. - Is a Certificate of Free Sale (CFS) mandatory for medical device registration in Colombia? - Which countries does INVIMA recognize as reference markets for prior approval? - How does device risk class affect the registration timeline and process in Colombia? - Can you register a novel medical device in Colombia without FDA approval or a CE mark? - What is the difference between INVIMA's "automatic" and "controlled" review pathways? - What is the function of INVIMA's Medical Device Reviewing Commission? - Are the requirements the same for both low-risk and high-risk devices? - What key decree governs medical device registration in Colombia? Pure Global provides comprehensive solutions for MedTech and IVD companies seeking to enter or expand in over 30 global markets, including Colombia. Our local experts and advanced AI tools streamline the entire process, from developing a regulatory strategy and compiling technical dossiers to acting as your official in-country legal representative. We accelerate market access and ensure ongoing compliance, allowing you to reach patients faster. Discover our free AI-powered regulatory tools and database at https://pureglobal.ai, or contact us at [email protected] and visit https://pureglobal.com to learn how we can support your global expansion.

This episode provides a detailed guide on the essential documents required for medical device registration in Colombia through the regulatory body, INVIMA. We cover the critical importance of the Certificate of Free Sale (CFS), the specific requirements for legalization and apostilles, the necessity of a local legal representative, and the comprehensive components of the technical file, including the mandatory Spanish language requirement. - What is the role of INVIMA in Colombia's medical device approval process? - Why is a Certificate of Free Sale (CFS) a mandatory document for registration? - What is an apostille, and when is it required for your submission documents? - Do foreign manufacturers need a local representative in Colombia? - What key information must be included in the technical file for INVIMA? - Is it possible to submit documents in English, or is Spanish mandatory? - What are the requirements for device labeling and Instructions for Use (IFU)? - How long is a medical device registration valid in Colombia? Pure Global offers expert regulatory consulting to streamline your MedTech or IVD company's entry into complex markets like Colombia. Our team acts as your local representative, leveraging in-country expertise and advanced AI tools to manage technical dossier submissions and ensure compliance with INVIMA's stringent requirements. We handle everything from regulatory strategy to post-market surveillance, allowing you to access over 30 global markets with a single, efficient process. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your global expansion.

This episode explores the medical device registration process in Colombia, focusing on the timelines set by the regulatory authority, INVIMA. We break down the key differences between the standard (controlled) review pathway for high-risk devices and the expedited (automatic) process for lower-risk devices, including eligibility requirements and realistic time-to-market estimates for each. This is essential information for any MedTech company considering market entry into Colombia. - What is INVIMA and what is its role in regulating medical devices in Colombia? - How long does the standard review process for Class IIb and III medical devices typically take? - What is the expedited or automatic registration pathway in Colombia? - Which device classes are eligible for the faster, automatic registration process? - What is a Certificate of Free Sale and why is it crucial for expedited entry? - Which foreign approvals does INVIMA recognize for its fast-track process? - How can manufacturers leverage existing FDA or CE approvals to speed up Colombian registration? - What are the realistic, real-world timelines for both the standard and expedited pathways? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies entering markets like Colombia. Our experts develop efficient regulatory strategies, leveraging pathways like INVIMA's automatic registration to accelerate your time-to-market. We manage the entire process, from compiling the technical dossier with AI-powered tools to acting as your local legal representative. With a presence in over 30 markets, we can turn a single registration process into multi-market access. To learn how we can help your company access global markets faster, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the mandatory requirement for a local authorized representative for medical device registration in Colombia. We explore the legal responsibilities this representative assumes as stipulated by the regulatory authority, INVIMA, under Decree 4725 of 2005. The discussion covers their central role in registration, post-market surveillance (technovigilance), and communication with authorities, while also highlighting the strategic importance of choosing an independent representative over a distributor to maintain market control. - Is a local representative required to sell medical devices in Colombia? - What are the specific legal duties mandated by INVIMA for this representative? - Who legally holds the product registration in Colombia—the manufacturer or the local representative? - What is the difference between a legal representative and an importer in Colombia? - How is post-market surveillance, or technovigilance, managed by the representative? - Which Colombian decree establishes the requirement for a local representative? - What are the risks of appointing a commercial distributor as your legal representative? - Why is selecting an independent third-party representative often the better long-term strategy? Pure Global offers end-to-end solutions for MedTech and IVD companies, streamlining global market access. We act as your local legal representative in over 30 countries, including Colombia, managing your registration submissions and ensuring ongoing compliance. Our experts, backed by advanced AI tools, help you develop efficient regulatory strategies, prepare technical dossiers, and monitor post-market activities. This integrated approach allows you to access multiple markets through a single, efficient process, saving time and resources. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Colombia's medical device risk classification system as regulated by INVIMA under Decree 4725 of 2005. We explain the four-tiered risk classes (Class I, IIa, IIb, and III), the criteria used for classification such as invasiveness and duration of use, and how a device's class determines its regulatory pathway for market approval in this key Latin American market. - What is the primary regulation governing medical device classification in Colombia? - How does INVIMA define Class I, IIa, IIb, and III medical devices? - What are the key factors used to determine a device's risk classification? - Why is correct classification the most critical first step for market entry in Colombia? - How does a device's risk class impact the INVIMA registration process and timeline? - Which international classification models is Colombia's system harmonized with? - Can you provide examples of devices for each of the four risk classes? - What is the difference in the regulatory pathway for low-risk versus high-risk devices? Pure Global offers end-to-end consulting to streamline your entry into over 30 global markets, including Colombia. Our local experts and advanced AI tools simplify complex regulatory challenges. We manage your technical dossier preparation, act as your official in-country representative for INVIMA, and develop a clear regulatory strategy to ensure your device meets all requirements under Decree 4725. With Pure Global, a single registration process can open doors to multiple markets, accelerating your global expansion efficiently. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI regulatory tools at https://pureglobal.ai.

This episode provides a comprehensive guide for foreign medical device manufacturers on registering their products in Colombia. We cover the role of the regulatory authority, INVIMA, the risk-based device classification system, and the essential documentation required for a successful submission, including the Certificate of Free Sale (CFS) and ISO 13485 certification. The host details the distinct timelines for low-risk and high-risk devices, explaining the expedited pathway for Class I and IIa products versus the more rigorous review for Class IIb and III devices. - What is INVIMA's role in the Colombian medical device market? - How does Colombia's risk-based classification system work? - Why is a local legal representative mandatory for foreign manufacturers? - What is a Certificate of Free Sale (CFS) and why is it essential? - Do technical documents and labeling need to be in Spanish? - What are the typical registration timelines for low-risk devices? - How long does it take to register high-risk devices in Colombia? - How long is a medical device registration valid for in Colombia? Pure Global streamlines global market access for MedTech and IVD companies. Our experts act as your local representative in over 30 markets, including Colombia, managing the entire INVIMA registration process. We develop efficient regulatory strategies and use advanced AI to compile and submit your technical dossiers, minimizing delays and ensuring compliance. Let us help you navigate the requirements for the Certificate of Free Sale, quality system documentation, and local regulations to get your product to market faster. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode breaks down the critical responsibilities of Economic Operators—Manufacturer, Authorised Representative, Importer, and Distributor—and the Person Responsible for Regulatory Compliance (PRRC) under the EU's MDR and IVDR. We explore the common operational pitfalls, such as role confusion, misaligned contracts, and PRRC coverage gaps, that frequently lead to audit findings and can jeopardize your market access in the European Union. Key Questions: - What are the four legally distinct Economic Operators under the EU MDR? - How do the responsibilities of an Importer differ from those of a Distributor? - Who is required to appoint a Person Responsible for Regulatory Compliance (PRRC)? - What are the primary duties of a PRRC in ensuring device compliance? - How can poorly defined contracts between operators lead to audit failures? - What are the risks of having a gap in your PRRC coverage? - Why is the Authorised Representative essential for non-EU manufacturers? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We specialize in defining clear regulatory strategies, including the proper setup of economic operator roles and PRRC responsibilities to ensure EU MDR and IVDR compliance. Our experts act as your local representative in over 30 markets, managing technical dossiers and post-market surveillance. By combining local expertise with advanced AI tools, we help you navigate complex regulations efficiently. Need to align your compliance framework? Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the growing tension between single-use medical devices and the push for sustainability. We delve into the complex world of reprocessing, examining the regulatory hurdles, validation requirements, and critical liability shifts under frameworks like the US FDA and the EU's Medical Device Regulation (MDR). We discuss how this trend impacts manufacturers, from Instructions for Use (IFU) to risk management, and what the future holds as the circular economy reshapes MedTech business models. Key Questions: - When is a single-use device no longer single-use? - Who becomes the legal manufacturer when a device is reprocessed? - What are the FDA and EU MDR requirements for device reprocessing? - How does reprocessing impact liability for the original manufacturer? - Why do Instructions for Use (IFU) need to be crystal clear about single-use claims? - What validation is needed to prove a reprocessed device is safe and effective? - How is the push for a circular economy changing medical device design and business strategy? - What new risks must be considered when reprocessing a medical device? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. Whether you're developing a regulatory strategy, compiling a technical dossier, or navigating post-market surveillance, our team can help. We act as your local representative in over 30 markets, using technology to accelerate approvals and ensure compliance. To access global markets faster and more efficiently, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the significant regulatory complexities for Companion Diagnostics (CDx) under the European Union's In Vitro Diagnostic Regulation (IVDR). We explore why these devices are now in a higher risk class, the impact of mandatory consultations with medicinal authorities like the EMA, and the critical need for seamless coordination between IVD manufacturers and their pharmaceutical partners to ensure timely market access. Key Questions: - What makes Companion Diagnostics (CDx) a unique challenge under the EU IVDR? - Why are most CDx considered high-risk Class C devices? - How does the mandatory consultation with the European Medicines Agency (EMA) impact timelines? - What are the new clinical evidence requirements for CDx performance evaluation? - How can IVD manufacturers and pharma partners align their regulatory strategies? - What happens if the drug and device timelines are not synchronized? - Why is early-stage coordination crucial for successful market entry? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access by combining local expertise in over 30 markets with advanced AI and data tools. Our services cover the entire lifecycle, from regulatory strategy and technical dossier submission to post-market surveillance. By leveraging a single registration process for multiple markets, we help you expand efficiently. Whether you're a startup or a multinational enterprise, our technology-driven solutions ensure compliance and speed. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode demystifies the requirements for In-Vitro Diagnostic (IVD) performance studies under the EU's IVDR. We explore the crucial guidance document, MDCG 2025-5, published in June 2024, to clarify common points of confusion for manufacturers. We cover the key differences between study notifications and applications, what constitutes a 'substantial modification,' the rules for using leftover samples, and how to manage combined studies, helping you avoid costly delays and regulatory rework. Key Questions: - What is the difference between a performance study notification and an application under IVDR? - When do I need to re-submit if I make changes to my study protocol? - Can we use leftover patient samples for our IVD performance study? - What does MDCG 2025-5 say about substantial modifications? - How does the EU regulate studies combining an IVD and a medicinal product? - Why is correctly classifying my IVD study crucial for avoiding delays? - What are the documentation requirements for studies using archived samples? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. Our experts, backed by advanced AI tools, streamline global market access. We develop efficient regulatory strategies for performance studies and pre-submission activities to minimize rejections. Our team handles the compilation and submission of technical dossiers, ensuring compliance with complex regulations like the EU IVDR. Whether you're a startup or a multinational, Pure Global provides the local expertise and technology-driven solutions to get your product to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed breakdown of the three pillars of performance evaluation required under the EU's In Vitro Diagnostic Regulation (IVDR): scientific validity, analytical performance, and clinical performance. We focus specifically on the heightened requirements and common pitfalls for manufacturers of high-risk Class C and D devices, explaining why underestimating the clinical evidence burden is a primary cause of delays in obtaining CE marking. - What are the three essential pillars of a successful IVDR performance evaluation? - Why is a Scientific Validity Report the foundational first step for your technical documentation? - What specific data is required to demonstrate analytical performance under the new regulation? - How has the burden for clinical performance evidence changed for Class C and D IVDs? - What are the most common reasons for CE marking delays related to performance studies? - How can you develop a robust clinical performance study plan that satisfies Notified Body scrutiny? - What is the critical difference between analytical performance and clinical performance in the eyes of regulators? Pure Global helps IVD companies conquer the challenges of global regulations like the EU IVDR. Our experts develop efficient regulatory strategies and manage the creation of technical dossiers, including complex Performance Evaluation Reports. We leverage advanced AI tools to streamline literature reviews and manage clinical data, ensuring your submission is robust and complete. Whether you're a startup or a multinational, we provide the support needed to navigate pre-submission activities and get your innovative IVDs to the European market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode delves into the critical requirements for medical device cybersecurity in the European Union. We explore the concept of "state of the art" as defined by the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), focusing on the key guidance document, MDCG 2019-16 Rev. 1. Learn how this guidance impacts your design controls, risk management, post-market surveillance, and change management processes to avoid common and costly audit nonconformities. - What does "state of the art" mean for medical device cybersecurity in the EU? - Why is MDCG 2019-16 Rev. 1 a critical document for your technical file? - How do you integrate "secure by design" principles into your product lifecycle? - Are your post-market surveillance activities adequately addressing cybersecurity vulnerabilities? - When does a cybersecurity patch trigger a significant change notification to your Notified Body? - What are the most common cybersecurity-related nonconformities in MDR and IVDR audits? - How does vulnerability handling connect to your vigilance reporting obligations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, ensuring compliance with complex requirements like cybersecurity. Our experts provide continuous regulatory monitoring to keep you ahead of changes that impact your market access. With a presence in over 30 markets, we act as your local representative, managing post-market surveillance and ensuring ongoing compliance. Let us help you navigate the global landscape. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the critical intersection of the new European Union AI Act and the existing Medical Device and In-Vitro Diagnostic Regulations (MDR/IVDR). We unpack the challenges of dual compliance for manufacturers of AI-enabled medical devices and explain how the recent joint guidance from the Medical Device Coordination Group and the Artificial Intelligence Board (MDCG 2025-6 / AIB 2025-1) provides a much-needed roadmap for integrating these two complex regulatory frameworks. Key Questions: - What is the EU AI Act and how does it specifically impact medical device manufacturers? - How do the requirements of the AI Act overlap with the existing MDR and IVDR? - What new information must be included in your technical documentation for an AI-enabled device? - How should risk management under ISO 14971 be integrated with the AI Act's risk framework? - What are the new post-market monitoring obligations specifically for AI systems? - Will your current Notified Body be able to assess your device for AI Act compliance? - What are the key deadlines that manufacturers need to be planning for right now? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We develop efficient regulatory strategies, act as your local representative in over 30 markets, and use powerful data tools to compile technical dossiers and monitor regulatory changes. To access global markets faster, visit us at https://pureglobal.com or contact [email protected]. Be sure to explore our FREE AI tools and extensive regulatory database at https://pureglobal.ai to support your compliance activities.

This episode explores the critical new regulatory focus from Europe's Medical Device Coordination Group (MDCG) on Software as a Medical Device (SaMD) distributed via online platforms. We discuss how the concept of 'making available on the market' now directly applies to app stores, forcing manufacturers to integrate platform listings, version control, and geographic restrictions into their core compliance and Quality Management Systems to avoid significant penalties. Key Questions: - What does 'making available on the market' mean for a medical app? - How can your app store listing create a serious compliance risk? - Are you responsible for ensuring only the correct version of your SaMD is downloadable? - How do you manage updates and change notices for an app distributed to thousands of users? - Can you use an app store's geographic restrictions to manage regulatory approvals? - What are the consequences of non-compliance for SaMD on digital marketplaces? - How does this new guidance impact your Quality Management System (QMS)? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a powerful combination of local expertise and advanced AI. For SaMD innovators, our experts develop efficient regulatory strategies and help manage technical dossiers for submission to authorities worldwide. We ensure your product remains compliant through post-market surveillance and continuous regulatory monitoring. Our AI-powered data tools can accelerate your research and document management. Let us help you navigate the complexities of global expansion. Visit us at https://pureglobal.com, contact [email protected], or explore our free AI tools and database at https://pureglobal.ai.

This episode delves into the critical definition of a "significant change" for legacy medical devices and IVDs under the EU MDR and IVDR. We explore the official MDCG guidance, outlining what types of modifications can end a device's transitional grace period, forcing an early and costly move to full certification. Learn about the high-stakes impact on market access and the importance of a robust change control process. - What is a "legacy device" and what are the new transition timelines? - How can a minor change to a device jeopardize its EU market access? - What is the difference between a significant and non-significant change? - Which MDCG guidance documents are essential for your change control process? - Why is changing a supplier a regulatory grey area? - What are the immediate consequences if a change is deemed significant? - How should you document and justify changes to your Notified Body? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We specialize in navigating complex transitions like the EU MDR and IVDR, offering services in Regulatory Strategy, Technical Dossier preparation, and Continuous Regulatory Monitoring to ensure your products remain compliant. Our unique combination of local expertise in over 30 markets and advanced AI tools streamlines global market access. Let us help you manage change control and maintain your market presence without disruption. Visit https://pureglobal.com, contact us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the complex realities of Unique Device Identification (UDI) strategy for medical devices. The host explores common blockers that go beyond simple barcode generation, including the nuanced rules for UDI assignment across different packaging configurations, the challenges of carrier placement, and the critical importance of database submission readiness for platforms like EUDAMED. We uncover why mistakes in UDI can cascade into significant traceability and recall issues, and discuss strategies for harmonizing labels across multiple international markets. Key Questions: - Why is UDI strategy more than just generating a number? - How do UDI requirements differ for individual devices versus kits or procedure packs? - What are the most common mistakes in assigning UDIs to different packaging levels? - How can you harmonize device labels for both US FDA and EU MDR compliance? - What makes EUDAMED data submission a critical blocker for market access? - How do UDI errors impact supply chain traceability and product recalls? - What are the rules for placing the UDI carrier on labels versus the device itself? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. We help develop efficient regulatory pathways, manage technical dossier submissions, and act as your local representative in over 30 markets. Our technology-driven approach enhances the accuracy and speed of compliance, from initial strategy to post-market surveillance. Let us help you navigate complex requirements and accelerate your international expansion. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the critical operational hotspots in medical device vigilance under regulations like the EU MDR. We examine the pressures for faster, higher-quality incident investigations, the complexities of making accurate MDR reportability decisions, and the nuances of establishing effective trend reporting thresholds. Discover how these vigilance activities are directly linked to your CAPA system, FSCA decisions, and the overall credibility of your Post-Market Surveillance (PMS) system during Notified Body audits. Key Questions: - How can you speed up incident investigations without sacrificing quality? - What are the key factors in making an accurate MDR reportability decision? - How do you establish meaningful thresholds for trend reporting? - What is the direct link between your vigilance system and your CAPA process? - How do Field Safety Corrective Actions originate from post-market vigilance data? - What will a Notified Body look for when auditing your incident-to-CAPA traceability? - Why is under-reporting incidents just as risky as over-reporting? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. Our experts help you build robust post-market surveillance and vigilance systems that meet stringent standards like the EU MDR. We develop efficient pathways for compliance, using advanced AI to manage technical dossiers and monitor regulatory changes. From initial strategy and registration to post-market surveillance and quality assurance, Pure Global ensures your products remain compliant and safe. Let us be your local representative and navigate complex vigilance requirements. Visit https://pureglobal.com/, email [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the critical shift in regulatory focus from Post-Market Surveillance (PMS) planning to execution. We discuss why Notified Bodies and regulators, particularly under the EU MDR, are no longer accepting PMS and Post-Market Clinical Follow-up (PMCF) as a paperwork exercise. Learn about the concept of a “silent nonconformity” and how a weak, poorly executed surveillance strategy can lead to major issues during surveillance audits and certificate renewals, jeopardizing your market access. - Why are regulators no longer accepting PMS plans as mere paperwork? - What is a “silent nonconformity” and how can it impact your device certification? - How can you design a PMS plan that generates truly usable signals about your device? - When is a Post-Market Clinical Follow-up (PMCF) study truly justified? - What are Notified Bodies looking for during a surveillance audit of your post-market activities? - How does the EU MDR change the expectations for PMS and PMCF execution? - Are your post-market surveillance activities prepared for the scrutiny of a renewal audit? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access by developing efficient regulatory strategies, including robust post-market surveillance and clinical follow-up plans. Our expert teams and advanced AI tools help you manage technical dossiers, monitor regulatory changes, and ensure ongoing compliance in over 30 markets. Avoid costly nonconformities and maintain your market presence with a proactive approach. To learn how we can accelerate your global expansion, visit us at https://pureglobal.com, contact [email protected], or explore our free AI tools and database at https://pureglobal.ai.

This episode delves into the stringent clinical evidence requirements under the European Union's Medical Device Regulation (MDR 2017/745). We explore the top challenges manufacturers face, including the heightened standards for clinical evaluation plans and reports (CEPs/CERs), the complexities of justifying 'sufficient data,' the difficulties in making equivalence arguments, and the continuous nature of Post-Market Clinical Follow-up (PMCF). Key Questions - What does "sufficient clinical evidence" truly mean under the EU MDR? - Why are so many companies forced to rewrite their Clinical Evaluation Reports (CERs)? - How have the rules for claiming equivalence to another device changed? - Is Post-Market Clinical Follow-up (PMCF) optional or a continuous requirement? - How do you align your marketing claims, risk management, and PMS data? - What are the biggest clinical data hurdles for borderline and Class IIa/IIb devices? - How can you prepare your clinical evaluation for stricter Notified Body scrutiny? Pure Global streamlines global market access for MedTech and IVD companies navigating complex regulations like the EU MDR. Our experts develop robust regulatory strategies and use advanced AI to efficiently compile technical dossiers and Clinical Evaluation Reports, ensuring alignment with Notified Body expectations. We manage the entire lifecycle, from pre-submission to Post-Market Clinical Follow-up and surveillance, acting as your local representative in over 30 markets. Let us help you meet the high standards for clinical evidence and accelerate your entry into the EU and beyond. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the ongoing Notified Body capacity crisis for EU MDR and IVDR certification. Despite extended transition deadlines, significant bottlenecks in audit scheduling and technical documentation review are creating a "timeline compression" risk. We explore why manufacturers must strategically prioritize their product portfolios and engage with Notified Bodies much earlier than planned to avoid jeopardizing market access as deadlines approach. - Why is Notified Body availability still a major risk despite MDR/IVDR deadline extensions? - What is "timeline compression" and how does it affect legacy devices? - How should manufacturers strategically prioritize products for EU certification? - What are the hidden delays in scheduling audits and technical file reviews? - Was the May 26, 2024 application deadline a false finish line? - Are the extended transition periods creating a false sense of security? - What steps can you take now to secure your place in the certification queue? Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI to accelerate global market access. We develop efficient regulatory strategies, assist with technical dossier submissions, and act as your local representative in over 30 markets to get your products approved efficiently. Our technology-driven approach streamlines compliance and market research, helping you navigate complex environments like the EU. Whether you are a startup or a multinational, we have scalable solutions to support your expansion. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode unpacks the European Commission's significant proposal of December 16, 2025, aimed at the targeted simplification of the MDR and IVDR. We explore the potential impacts on documentation, digitalization through EUDAMED, and what these changes could mean for manufacturers, especially SMEs, as they navigate the complex European regulatory landscape. Key Questions: - What specific changes are included in the EU Commission's "targeted simplification" proposal? - How could the proposed MDR/IVDR updates affect documentation and compliance costs? - What role will digitalization and the mandatory use of EUDAMED play in the future? - Are Small and Medium-sized Enterprises (SMEs) specifically addressed in this proposal? - What is the legislative timeline, and when might these changes take effect? - Should manufacturers alter their current regulatory strategy based on this news? - How will the proposal impact market access and device availability in the EU? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. We develop efficient pathways for regulatory approval, using AI to compile and submit technical documents, and act as your local representative in over 30 markets. Whether you're a startup or a multinational enterprise, our technology-driven approach ensures you can navigate complex environments and bring innovations to market faster. Visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode unpacks the critical amendments introduced by Regulation (EU) 2024/1860, focusing on the new obligations for medical device manufacturers to notify authorities about supply interruptions and discontinuations. We explore why this has become a major compliance challenge, touching on its impact on portfolio management, distributor relations, and the necessity for early risk detection systems to prevent shortages and ensure market stability in the European Union. - What are the new supply shortage notification rules under EU Regulation 2024/1860? - When must a manufacturer inform authorities about discontinuing a medical device? - Why is supply continuity now a major compliance hotspot in the EU? - How does this regulation affect your product portfolio and end-of-life planning? - What systems should you have in place to flag potential supply interruptions early? - How should communication with distributors be managed in light of these new rules? - What are the potential consequences of failing to comply with these notification requirements? Navigating complex regulations like the EU's new supply continuity rules is essential for maintaining market presence. Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, ensuring you stay compliant across more than 30 global markets. Our experts develop clear regulatory strategies and use advanced AI to monitor regulatory changes, helping you anticipate challenges and maintain uninterrupted market access. We act as your local representative, handling communications with authorities so you can focus on your business. For support, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the crucial extension of the In-Vitro Diagnostic Regulation (IVDR) transition periods under the EU's Regulation 2024/1860. We explore the specific, time-sensitive conditions manufacturers must meet to benefit from this extension, including Quality Management System requirements and mandatory engagement with a Notified Body. This is essential information for any IVD manufacturer looking to maintain market access in the European Union. - What is Regulation (EU) 2024/1860 and how does it affect your IVD products? - Are your legacy devices eligible for the new IVDR transition extension? - What specific conditions must be met to keep your products on the EU market? - By when must you have a compliant Quality Management System in place? - What are the crucial deadlines for applying to and signing an agreement with a Notified Body? - What constitutes a 'significant change' that could void your eligibility? - How can you start preparing your application for a notified body right now? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use AI to compile technical dossiers. Our team helps you maintain compliance through post-market surveillance and continuous regulatory monitoring, ensuring your products meet international standards. Whether you're a startup or a multinational, we provide tailored solutions for your expansion needs. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the crucial update on the EUDAMED gradual roll-out. We explain the impact of the European Commission's Implementing Decision (EU) 2025/2371, which confirms the functionality of the first four EUDAMED modules. The discussion covers which modules are now live, the official start date for mandatory use—May 28, 2026—and what actions medical device and IVD manufacturers must take to ensure compliance for market access in the European Union. Key Questions: - What is Commission Implementing Decision (EU) 2025/2371 and why is it important? - Which four EUDAMED modules are now officially considered functional? - What is the exact date that mandatory use of these EUDAMED modules begins? - How does the gradual roll-out affect registrations for new and legacy medical devices? - What are the immediate actions manufacturers must take to prepare for the 2026 deadline? - Will the Vigilance and Clinical Investigation modules also be mandatory in 2026? - What is a Single Registration Number (SRN) and why is it essential? Struggling with complex regulatory changes like the EUDAMED rollout? Pure Global offers end-to-end consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using advanced AI to compile technical dossiers. Our services cover the entire product lifecycle, from initial market research to post-market surveillance. Let us help you navigate the EU market with confidence. Visit us at https://pureglobal.com/, contact [email protected], or explore our free AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Mexico's three-tiered medical device classification system managed by COFEPRIS. We explore how Class I, Class II, and Class III devices are defined by risk and highlight the key differences between Mexico's framework and the systems used by the US FDA and the European Union. Understanding these nuances is the critical first step for successful market entry. - How does Mexico's COFEPRIS classify medical devices? - What are the three risk-based classes for medical devices in Mexico? - Is there a special category for low-risk Class I devices in Mexico? - Can a device's US FDA classification be used for registration in Mexico? - How does Mexico's 3-class system differ from the EU's 4-class model? - Why is it a mistake to assume classifications are the same across regions? - Which regulation governs device classification in Mexico? - What determines the regulatory pathway and cost for market access in Mexico? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using AI to compile and submit technical dossiers. Our integrated approach allows a single registration process to access multiple markets, saving you time and resources. To accelerate your global expansion and ensure ongoing compliance, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the critical error of applying South Korea's four-tier MFDS medical device classification directly to Mexico's three-tier COFEPRIS registration system. We explain why the differing regulatory frameworks, classification rules, and risk criteria make a direct transfer impossible and discuss the severe consequences of such a mistake, including immediate rejection, costly delays, and reputational damage with the regulatory authority. - Why is it a mistake to use a Korean device classification for a Mexican market submission? - What are the primary differences between the MFDS and COFEPRIS classification systems? - How many risk classes for medical devices exist in South Korea versus Mexico? - What are the consequences of submitting a device to COFEPRIS with the wrong classification? - Can a device's risk level change when moving from the Korean to the Mexican market? - How do different national regulations impact global market access strategy? - What is the first step to ensure a smooth registration process in Mexico? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. Our experts develop efficient regulatory strategies, leveraging a single registration process to access over 30 markets, including Mexico and South Korea. We use advanced AI and data tools to compile technical dossiers, manage submissions, and provide continuous regulatory monitoring, ensuring your products meet local standards from initial strategy to post-market surveillance. Let us handle the complexities of COFEPRIS and MFDS regulations. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode focuses on the critical regulatory hurdles Korean medical device companies face when entering the Mexican market. We delve into the specifics of COFEPRIS's three-tier classification system, highlighting its key differences from Korea's four-class MFDS framework. Listeners will learn why misclassification is a primary cause of submission rejections and how a strategic approach to device grouping can significantly reduce registration costs and timelines, ensuring a smoother and more efficient market entry into Mexico. Key Questions: - How does Mexico's COFEPRIS device classification differ from Korea's MFDS system? - What are the most common reasons for COFEPRIS submission rejections? - Why is a device grouping strategy essential for entering the Mexican market? - How can you minimize costs and delays when registering multiple devices in Mexico? - What international frameworks influence Mexico's medical device regulations? - Are there specific nuances Korean manufacturers must know before submitting to COFEPRIS? Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining your path to international markets. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers for markets like Mexico. We act as your local representative in over 30 countries, ensuring your products achieve and maintain compliance. Whether you are a startup or a multinational, our technology-driven solutions accelerate your global expansion. For a consultation, contact [email protected] or visit https://pureglobal.com. Explore our free regulatory AI tools and database at https://pureglobal.ai.

This episode explores the transformative Abbreviated Regulatory Pathway being launched by Mexico's COFEPRIS in September 2025. We detail how this new 30-day process specifically benefits Korean medical device manufacturers holding MFDS approval, outlining the immense opportunity for accelerated market entry. The discussion also covers critical challenges, such as proving product equivalency and navigating submission requirements, to help companies leverage this shortcut effectively. - What is Mexico's new Abbreviated Regulatory Pathway for medical devices? - When does the new COFEPRIS 30-day approval process take effect? - How can Korean companies leverage their existing MFDS approval for faster market access in Mexico? - What are the key requirements for proving product equivalency between Korean and Mexican submissions? - How can you avoid common pitfalls when using this new expedited pathway? - What does this regulatory change mean for the Latin American MedTech market? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies seeking to accelerate global market entry. Our experts specialize in developing efficient regulatory strategies, like leveraging Mexico's new 30-day abbreviated pathway for MFDS-approved devices. We act as your local representative in over 30 markets, using advanced AI to compile and submit technical dossiers that minimize rejections. Whether you are a startup or a multinational, Pure Global provides the local expertise and technology-driven solutions needed to navigate complex regulatory environments. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explains the mandatory requirement for foreign medical device manufacturers to appoint a Mexico Registration Holder (MRH) to register products with COFEPRIS. It highlights the specific challenges Korean companies face in finding a reliable partner and the risks of appointing a distributor for this role. The host details how a dedicated, professional MRH provides a secure and compliant pathway to the Mexican market. - What is the single most critical step for Korean MedTech companies entering the Mexican market? - Why can't foreign medical device companies register their products directly with Mexico's COFEPRIS? - What are the core responsibilities of a Mexico Registration Holder (MRH)? - How does appointing a sales distributor as your MRH create significant business and compliance risks? - What are the key advantages of using an independent, professional registration holder? - How can you maintain full control of your medical device registration in Mexico? - What should you look for in a trustworthy local regulatory partner in Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. As your dedicated Mexico Registration Holder (MRH), we manage your COFEPRIS submissions, ensure ongoing compliance, and provide a secure, independent partnership. Our AI-powered tools and expert team help you navigate complex regulatory pathways efficiently, giving you full control over your market presence. To learn how we can accelerate your entry into over 30 global markets, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools at https://pureglobal.ai.

This episode focuses on the single most critical challenge for Korean medical device companies entering the Mexican market: the stringent Spanish language requirements mandated by the regulatory authority, COFEPRIS. We explore how this impacts the entire registration process, from technical documentation to labeling, and why overcoming this linguistic barrier is fundamental for successful market access. Key Questions: - Why is Spanish proficiency the top regulatory hurdle for Korean device manufacturers in Mexico? - What are COFEPRIS's specific language rules for technical dossiers and official communications? - How does the requirement extend beyond documents to product labeling and instructions for use? - What are the risks of using direct or machine translation for regulatory submissions? - How can in-country, native-speaking consultants de-risk the market entry process? - What challenges do Korean SMEs, accustomed to domestic business, face with international documentation? - How does proper localization differ from simple translation in the eyes of regulators? Pure Global offers end-to-end solutions for MedTech and IVD companies seeking to navigate complex regulatory landscapes like Mexico's. Our local experts and advanced AI tools streamline global market access, from regulatory strategy and technical dossier preparation to acting as your official in-country representative. We turn regulatory hurdles into strategic advantages, helping you get to market faster. For support with your expansion into Mexico or over 30 other countries, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores why Brazil is a critical entry point for Korean medical device companies looking to expand into South America. We discuss how to leverage Brazil's position within the MERCOSUR trade bloc to access markets like Argentina, Paraguay, and Uruguay, turning a single-country registration into a regional strategy. - Why is Brazil more than just a large domestic market for Korean medical device firms? - What is MERCOSUR and how does it benefit MedTech companies entering South America? - Can a Brazilian registration be used to sell devices in Argentina or Uruguay? - What are the common pitfalls when expanding from Brazil into other MERCOSUR countries? - How can Korean companies leverage Brazilian partnerships for regional success? - What are the duty-free advantages of the MERCOSUR trade bloc? - Are the regulatory processes in MERCOSUR countries identical? For MedTech and IVD companies, navigating a regional strategy across MERCOSUR requires deep local expertise. Pure Global acts as your local representative in over 30 markets, including Brazil and other key American countries. We develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, helping you leverage a single process for multiple market entries. Our local experts ensure you navigate each country's specific requirements for successful expansion. For a consultation, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.